CAS 2381089-83-2 · MW 4731.33 · C₂₂₁H₃₄₂N₄₆O₆₈. Novel Eli Lilly peptide — the only research compound simultaneously activating GLP-1R (EC₅₀ 0.775 nM), GIPR (EC₅₀ 0.064 nM), and GCGR (EC₅₀ 5.79 nM). The GCGR component drives direct hepatic fat oxidation and thermogenesis that semaglutide (GLP-1R only) and tirzepatide (GLP-1R + GIPR) cannot achieve. Phase 2 data: 15–24% mean weight reduction at 48 weeks — highest published for any GLP-1-class compound.
Retatrutide 10mg | 10-Vial Kit 10mg/vial · 100mg total
CAS 946870-92-4 · MW ~9,111 · 83 amino acids. Modified IGF-1 with Arg³ substitution (reduces hypoglycaemic activity) and 13-AA N-terminal extension (reduces IGFBP binding → extends half-life to 20–30 hours from 12 minutes). Activates IGF-1R → PI3K/Akt (anabolic/anti-apoptotic) and MAPK/ERK (proliferative). ~13× more effective per molecule than standard IGF-1 for sustained receptor activation.
7. Testosterone Cypionate 250mg/mL — Androgenic Foundation
CAS 58-20-8 · MW 412.61. Cyclopentylpropionate ester for 7–10 day sustained androgen release. Binds AR to regulate nitrogen retention, protein synthesis, erythropoiesis, bone mineral density. Androgenic-anabolic foundation for the stack. Oil injectable, 250mg/mL, 10mL/vial.
CAS 137525-51-0 · MW 1419.53. Stable 15-AA gastric pentadecapeptide. Modulates NO pathway signaling, EGF/FGF/VEGF growth factor upregulation, FAK-paxillin-paxillin integrin cascade. Researched for tendon/ligament healing, GI barrier repair, neuroprotection, anti-inflammatory effects. Core ClavTides compound — paired with TB-500 in every major community protocol.
BPC-157 10mg | 10-Vial Kit 10mg/vial · 100mg total
12. Anavar (Oxandrolone) 25mg — Cortisol Control (NEW)
CAS 53-39-4 · MW 306.44. DHT-derived oral anabolic. Anabolic:androgenic ratio ~322:24. Downregulates glucocorticoid receptor (GR), reducing cortisol-mediated catabolism. In a caloric-deficit recomposition protocol amplified by Retatrutide, anti-catabolic cortisol management is mechanistically relevant. Confirmed in Clavicular’s NYT interview and Looksmax.org protocol posts. 25mg/tablet × 100 tablets.
Retatrutide adds GCGR (glucagon receptor) agonism to GLP-1R + GIPR, creating three simultaneous mechanisms. The GCGR component drives direct hepatic fat oxidation and thermogenesis that dual-agonists like Tirzepatide cannot achieve. Phase 2 data showed ~24% mean weight reduction for Retatrutide vs ~20.9% for Tirzepatide — the difference is primarily attributable to the GCGR pathway.
Why is IGF-1 LR3 used instead of standard IGF-1?
IGF-1 LR3 has a half-life of 20–30 hours versus 12 minutes for standard IGF-1. The Arg³ substitution and 13-AA extension reduce IGFBP binding, dramatically extending circulation time. Per molecule, IGF-1 LR3 is approximately 13× more potent for sustained IGF-1R activation in research settings.
What role does Anavar play in the Ascension Stack?
Oxandrolone provides glucocorticoid receptor (GR) downregulation, reducing cortisol-mediated catabolism. In a recomposition protocol driven by Retatrutide’s caloric deficit amplification, anti-catabolic protection is mechanistically relevant. It was confirmed in Clavicular’s NYT interview as part of the documented protocol.
Why are BPC-157 and TB-500 used together?
BPC-157 modulates NO pathways, growth factor signaling (EGF/FGF/VEGF), and FAK-paxillin integrin cascades. TB-500 governs actin-binding cell migration, cytoskeletal dynamics, and angiogenesis. Their mechanisms are complementary — different targets, synergistic outcomes. This ClavTides pairing is one of the most-researched peptide combinations for tissue repair.
What is the difference between CJC-1295 No DAC and With DAC?
No DAC has a ~30-minute half-life, producing pulsatile GH release matching natural GH rhythms. With DAC uses a Drug Affinity Complex to extend half-life to ~8 days, causing sustained GH elevation. The Ascension Stack specifically uses No DAC to preserve physiological pulsatile patterns and avoid receptor desensitisation.
